What does the evidence say about Myo-Inositol Insulin Sensitivity Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Myo-Inositol Insulin Sensitivity Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - The global prevalence of PCOS increased from 36.7 to 69.5 million between 1990 and 2021. [Subakathulla Sumayyah (2026); evidence level 3] - Emerging evidence underscores that OS is not a mere byproduct of metabolic imbalance but a central driver that disrupts insulin signaling, amplifies androgen biosynthesis, and impairs folliculogenesis (,). [Subakathulla Sumayyah (2026); evidence level 3] - Low-dose variants of OCPs have been observed with an increased risk of myocardial infarction and cardiovascular arterial disease (). [Subakathulla Sumayyah (2026); evidence level 3] - 1 2 3 4 5 Polycystic ovary syndrome (PCOS) represents one of the most complex endocrine-metabolic disorders affecting women of reproductive age, characterized by a collection of reproductive, metabolic, and psychological manifestations (,). [Subakathulla Sumayyah (2026); evidence level 3] - 1 2 3 4 Polycystic ovary syndrome (PCOS) is among the most frequent endocrine disorders in women of reproductive age and is strongly associated with multiple cardiometabolic disturbances. [Muacevic Alexander (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.